Related Experiment Video

Updated: Jul 3, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Cefepime and its role in pediatric infections

Sukhbir K Shahid1

  • 1Consultant Pediatrician and Neonatologist, Mumbai-400 077, India. sukhbir5@lycos.com

Recent Patents on Anti-Infective Drug Discovery
|August 5, 2008
PubMed

Insights

Cefepime, a fourth-generation cephalosporin antibiotic, offers broad-spectrum coverage against resistant bacteria, including those producing extended-spectrum beta-lactamases. Judicious use is crucial to maintain its efficacy in treating pediatric infections.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Pediatrics

Background:

  • Cefepime is a fourth-generation cephalosporin antibiotic.
  • It exhibits broad-spectrum activity against Gram-positive and Gram-negative bacteria.
  • Its efficacy against multi-drug resistant organisms and extended-spectrum beta-lactamase (ESBL)-producing pathogens makes it valuable.

Purpose of the Study:

  • To review the antimicrobial activity and clinical applications of cefepime.
  • To highlight its role in treating severe and nosocomial infections in children.
  • To discuss its safety profile, dosing considerations, and emerging developments.

Main Methods:

  • Literature review of cefepime's properties and clinical use.
  • Analysis of its efficacy against resistant bacterial strains.
  • Examination of recent advancements and patents related to cefepime.

Main Results:

  • Cefepime demonstrates superior bactericidal action compared to other cephalosporins.
  • It is effective against beta-lactamase and ESBL-secreting pathogens.
  • Dose adjustments are necessary for newborns and children with renal insufficiency.

Conclusions:

  • Cefepime is a safe, effective, and cost-efficient alternative to carbapenems for various infections.
  • Judicious use is essential to prevent resistance and maintain efficacy.
  • New developments, including combinations with beta-lactamase inhibitors, may enhance its utility in pediatric infections.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...